Brivaracetam add-on treatment in pediatric patients with severe drug-resistant epilepsy: Italian real-world evidence.

Brivaracetam (BRV) is a recently released antiepileptic drug (AED), currently approved as adjunctive therapy for focal seizures in patients aged 4 years and older in the European Union, and as monotherapy and adjunctive therapy in patients aged 4 years and older in the United States (US) [1,2]. BRV is a 2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide, with four different diastereomers, with high-affinity binding to SV2A [3,4]. This mechanism of action partially mirrors that of levetiracetam (LEV), a previously discovered and widely used AED.

0